PHYHEALTH Corp - FORM 10-Q

Attached files

file	filename
EXCEL - IDEA: XBRL DOCUMENT - PHYHEALTH Corp	Financial_Report.xls
EX-32.1 - CERTIFICATION - PHYHEALTH Corp	phy_ex321.htm
EX-31.1 - CERTIFICATION - PHYHEALTH Corp	phy_ex311.htm
EX-31.2 - CERTIFICATION - PHYHEALTH Corp	phy_ex312.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2012

o TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the transition period from _________________ to ________________

COMMISSION FILE NUMBER: 333-163076

PHYHEALTH CORPORATION

(Exact name of registrant as specified in its charter)

Delaware		26-1772160
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

700 South Royal Poinciana Boulevard -- Suite 506

Miami, Florida 33166

(Address of principal executive offices)

(305) 779-1760

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ¨Yes xNo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	o	Smaller reporting company	x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o Yes x No

The number of outstanding shares of the registrant's common stock, par value $.0001, was 11,181,572 as of May 18, 2012.

TABLE OF CONTENTS

		Page #

PART 1	FINANCIAL INFORMATION:

ITEM 1	FINANCIAL STATEMENTS:

	Phyhealth Corporation Consolidated Financial Statements for the three Months Ended March 31, 2012 and 2011.	1

ITEM 2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	16

ITEM 3	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	20

ITEM 4	CONTROLS AND PROCEDURES	20

PART II	OTHER INFORMATION:

ITEM 1	LEGAL PROCEEDINGS	21

ITEM 1A	RISK FACTORS	21

ITEM 2	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	21

ITEM 3	DEFAULTS UPON SENIOR SECURITIES	21

ITEM 4	MINE SAFETY DISCLOSURES	22

ITEM 5	OTHER INFORMATION	22

ITEM 6	EXHIBITS	22

	Signatures	23

PART I -- FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Phyhealth Corporation and Subsidiaries

Consolidated Financial Statements

For the three months ended March 31, 2012 and 2011

Phyhealth Corporation and Subsidiaries

Index to Consolidated Financial Statements

	Page

Consolidated Balance Sheets	3

Consolidated Statements of Operations and Comprehensive Loss – Unaudited	4

Consolidated Statements of Changes in Stockholders’ Deficit – Unaudited	5

Consolidated Statements of Cash Flows – Unaudited	6

Notes to Consolidated Financial Statements – Unaudited	6

Phyhealth Corporation and Subsidiaries

Consolidated Balance Sheets

	March 31, 2012			December 31,2011
ASSETS	(unaudited)
Current assets:
Cash	$	6,537		$	28,233
Patient receivables, net of $60,684 and $73,395 allowance at		77,676			65,889
March 31, 2012 and December 31, 2011, respectively.
Marketable equity securities		9,200			2,415
Due from related party affiliate		1,238			21,656
Other current assets		11,000			7,500
Total current assets		105,651			125,693

Property, furniture and equipment, net		196,062			204,389
Other assets		13,375			11,433
Intangible - accreditation, net		15,505			-
Total assets	$	330,593		$	341,515

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable and accrued liabilities	$	259,079		$	166,203
Accrued payroll liabilities		169,757			107,081
Loan payable to related party officer and spouse		218,278			25,000
Note payable to related party affiliate		-			50,000
Current portion of capital leases		76,694			74,904
Convertible notes payable to related party officer, net of $0 and $3,876
discount on March 31, 2012 and December 31, 2011, respectively.		300,000			296,124
Total current liabilities		1,023,808			719,312

Capital leases, net of current portion		78,276			97,960
Total Liabilities		1,102,084			817,272

Commitment and Contingencies (Notes 4 and 5)

STOCKHOLDERS' DEFICIT:
Common stock, $0.0001 par value, 40,000,000 authorized, 11,181,572 and 11,031,572
issued and outstanding at March 31, 2012 and December 31, 2011, respectively.		1,118			1,103
Preferred stock, 10,000,000 authorized, $0.0001 par value,
Series A convertible preferred stock, 5,000,000 designated, 2,964,469 shares
issued and outstanding at March 31, 2012 and December 31, 2011, respectively		296			296
Series B convertible preferred stock, 5,000,000 designated, 612,489 shares
issued and outstanding at March 31, 2012 and December 31, 2011, respectively		61			61
Additional paid-in capital		2,569,871			2,527,436
Accumulated deficit		(3,247,037	)		(2,902,068	)
Accumulated other comprehensive loss-unrealized loss on marketable equity securities		(95,800	)		(102,585	)
Total stockholders' deficit		(771,491	)		(475,757	)
Total liabilities and stockholders' deficit	$	330,593		$	341,515

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Phyhealth Corporation and Subsidiaries

Consolidated Statements of Operations and Comprehensive Loss - Unaudited

	Three months ended March 31:
	2012			2011

Sleep care services revenue, net	$	107,253		$	53,243

Operating expenses:
Officer and director compensation and related costs		85,415			79,901
Consulting and professional fees		47,311			100,206
Sleep center operating expense		191,434			109,521
Bad debt expense		-			29,917
General and administration		106,344			80,591
Total operating expense		430,504			400,136
Loss from operations		(323,251	)		(346,893	)

Other income (expenses):
Interest expense		(50,402	)		(2,707	)
Realized gain on sale of securities		-			147,855
Gain on settlement of note payable		28,684			-
Total other income (expense)		(21,718	)		145,148
Net loss		(344,969	)		(201,745	)
Add: net loss attributable to noncontrolling interest		-			2,265
Net loss attributable to Phyhealth Corporation and Subsidiaries	$	(344,969	)	$	(199,480	)
Net loss per share - basic and diluted	$	(0.03	)	$	(0.03	)

Weighted average shares outstanding - basic and diluted		11,179,924			6,604,312

Net loss	$	(344,969	)	$	(201,745	)
Unrealized investment holding gain (loss)		6,785			(73,907	)
Less: reclassification adjustment for (gain) loss included in net loss		-			(147,855	)
Comprehensive loss		(338,184	)		(423,507	)
Net loss attributable to noncontrolling interest		-			2,265
Comprehensive loss attributable to Phyhealth Corporation and Subsidiaries	$	(338,184	)	$	(421,242	)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Phyhealth Corporation and Subsidiaries

Consolidated Statements of Changes in Stockholders' Deficit - Unaudited

For the three months ended March 31, 2012

																		Accumulated
	Series A				Series B								Additional					Other			Total
	Preferred Stock				Preferred Stock				Common Stock				Paid-in		Accumulated			Comprehensive			Stockholders'
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Income (Loss)			Deficit

Balance- December 31, 2011		2,964,469	$	296		612,489	$	61		11,031,572	$	1,103	$	2,527,436	$	(2,902,068	)	$	(102,585	)	$	(475,757	)

Issuance of shares on acquisition		-		-		-		-		150,000		15		12,435		-			-			12,450

Beneficial Conversion feature		-		-		-		-		-		-		30,000		-			-			30,000

Change in unrealized loss on marketable equity securities		-		-		-		-		-		-		-		-			6,785			6,785

Net loss for three months ended March 31, 2012
Net loss for three months ended March 31, 2012		-		-		-		-		-		-		-		(344,969	)		-			(344,969	)

Balance - March 31, 2012		2,964,469	$	296		612,489	$	61		11,181,572	$	1,118	$	2,569,871	$	(3,247,037	)	$	(95,800	)	$	(771,491	)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Phyhealth Corporation and Subsidiaries

Consolidated Statements of Cash Flows - Unaudited

	Three months ended March 31,
	2012			2011
Cash from operating activities:
Net loss attributable to Phyhealth Corporation and Subsidiaries	$	(344,969	)	$	(199,480	)
Adjustments to reconcile net loss to net cash used in operating activities:
Net loss attributable to noncontrolling interests		-			(2,265	)
Gain on sale of securities		-			(147,855	)
Gain on settlement of note payable		(28,344	)		-
Beneficial conversion feature amortized		30,000			-
Bad debt expense		-			29,917
Depreciation and amortization		19,972			7,448
Amortization of debt discount		3,876			-
Changes in operating assets and liabilities:
Patient receivable, net		(11,787	)		(20,386	)
Other current assets		(3,500	)		(1,500	)
Due from related party		(1,238	)		(8,095	)
Other assets		(1,942	)		(3,000	)
Accounts payable and accrued liabilities		101,454			16,418
Accrued payroll liabilities		62,676			11,458
Net cash used in operating activities		(173,802	)		(317,340	)

Cash flows from investing activities:
Proceeds from sale of marketable securities		-			423,543
Purchase of property, furniture & equipment		-			(11,194	)
Net cash provided by investing activities		-			412,349

Cash flows from financing activities:
Proceeds from margin loan		-			(137,609	)
Proceeds from related party loan		170,000			-
Repayment of capital lease		(17,894	)		(3,553	)
Net cash provided (used) by financing activities		152,106			(141,162	)

Net decrease in cash		(21,696	)		(46,153	)
Cash, beginning of period		28,233			112,087
Cash, end of period	$	6,537		$	65,934

Supplemental disclosures of cash flow information:
Interest paid in cash	$	3,372		$	1,285
Income taxes paid in cash	$	-		$	-

Non-cash investing and financing activities:
Debt discount for beneficial conversion value	$	30,000		$	-

Unrealized (gain) loss on investments	$	(6,785	)	$	73,907
Equipment purchases under capital lease	$	-		$	85,928
Acquisition of Sleep Center:
Assets acquired	$	27,450		$	-
Common stock issued		(12,450	)		-
Liability incurred		(15,000	)		-
Net cash received from acquisition of sleep center	$	-		$	-

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Phyhealth Corporation and Subsidiaries

Notes to Consolidated Financial Statements - Unaudited

For the three months ended March 31, 2012 and 2011

1. BASIS OF PRESENTATION, PRINCIPLE OF CONSOLIDATION, ORGANIZATION, NATURE OF BUSINESS, BASIS OF PRESENTATION AND GOING CONCERN

Basis of Presentation – The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of consolidated financial position and results of operations. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair consolidated financial statement presentation. The results for the interim period are not necessarily indicative of the results to be expected for the year. For further information, refer to the audited consolidated financial statements and footnotes of the company for the years ending December 31, 2011 and 2010.

Principles of Consolidation - The consolidated financial statements include the accounts of Phyhealth Corporation which is a Delaware corporation and includes its wholly-owned and majority-owned subsidiaries as described below. All material intercompany balances and transactions have been eliminated in consolidation.

Organization – Phyhealth Corporation (“Company,” “Phyhealth” or “Parent”) was formed in the state of Delaware on January 18, 2008 and was originally a wholly-owned subsidiary of Physicians Healthcare Management Group, Inc. (PHMG).

Subsidiaries – As part of the Spinoff from PHMG that occurred in 2010, Phyhealth acquired PHMG’s ownership interest in the following subsidiaries:

Phyhealth Underwriters, Inc. - On July 1, 2005, Phyhealth Underwriters, Inc. (Underwriters) was incorporated in the state of Illinois. On December 12, 2005 it was redomesticated by incorporating in Nevada. It was originally owned equal between two partners. On February, 27, 2009 the Company purchased an additional 42.5% (1,062 shares) of the common stock of Phyhealth Underwriters, Inc. (Underwriters) for a total of 92.5% ownership from its joint venture partner, Atlas Insurance Management (Atlas). Underwriters was created to act as the legally required Attorney-in-fact for risk retention groups such as the one formed by the Company and Atlas named “Physhield Insurance Exchange, a Risk Retention Group” (Physhield), a Nevada domiciled Association Captive. Underwriters was the Attorney-in fact for Physhield, but Physhield was liquidated between April and June of 2011 as described below. Underwriters was liquidated on December 27, 2011.

Florida Physicians - On November 29, 2007, the Company filed with the state of Florida to create a limited liability company named Florida Physicians, LLC (Florida Physicians). Phyhealth is the managing member of Florida Physicians, which in turn is the immediate parent of Phyhealth Plan Corporation as described below.

Phyhealth Plan Corporation - On September 4, 2007 the Company filed with the state of Florida to create Phyhealth Plan Corporation (Plancorp). There were 10 million, no par, shares authorized upon filing. This wholly owned subsidiary of Florida Physicians was created to operate as a health maintenance organization (HMO).

Phyhealth Sleep Care Corporation - On September 29, 2010, Phyhealth Sleep Care Corporation (Phyhealth Sleep Care) was incorporated in the state of Delaware in order to own and operate sleep care facilities.

Newly Formed Subsidiary:

Phyhealth Sleep Care Colorado, Inc. - On February 3, 2012, Phyhealth Sleep Care Colorado, Inc. (Phyhealth Sleep Colorado) was incorporated in the state of Wyoming in order to own and operate sleep care facilities in Colorado.

Phyhealth Corporation and Subsidiaries

Notes to Consolidated Financial Statements - Unaudited

For the three months ended March 31, 2012 and 2011

Nature of Business and Current Operations –The Company is marketing to physicians and physician groups.

The Company’s intended core product is the development of community health plans - based on a health maintenance organization (HMO) license- that are owned and operated in partnership with the participating physicians. The Company’s community health plan structure integrates all the financial and reimbursement components of healthcare delivery; aligns the financial incentives of all participants; and empowers physicians to assume end-to-end management of healthcare for their patients. The Phyhealth community health plan model is built on the foundation of the physician-patient relationship and rewards physicians for proactively providing the preventative care necessary to keep their patients healthy and for closely managing the ongoing care necessary for patients who suffer from chronic disorders to stabilize their health status.

Through its planned community health plan operations, the Company intends to expand its product offerings to include ownership and operation of local healthcare facilities and other products and services designed to support its goal to increase physicians’ income, reduce their expenses and add to their net worth.. Part of this plan was initiated in October 2010 when the Company incorporated a wholly owned subsidiary named Phyhealth Sleep Care Corporation (Sleep Care) and entered into an agreement with an individual operator to open a series of sleep care centers over the next year. In November 2010 Sleep Care initiated the development of a 2-bed diagnostic sleep center in Longmont, Colorado and purchased the assets and assumed certain liabilities of an existing 2-bed diagnostic sleep care center in Denver, Colorado. In January 2011, the Denver facility was expanded to 4 beds. In June 2011 Sleep Care opened a 4-bed diagnostic sleep center in Virginia. In December 2011, the Company closed the Denver facility coincident with the expiration of the leases for this facility, and in January 2012, the Company purchased a 2-bed facility in Brighton, Colorado. (see Note 4 – Sleep Center Acquisition).

Going Concern - The accompanying unaudited consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company and its ability to meet its ongoing obligations. The Company has a net loss attributable to Phyhealth Corporation and its subsidiaries of $344,969 and net cash used in operations of $173,802 for the three months ended March 31, 2012 and a negative working capital, stockholders’ deficit and an accumulated deficit of $918,157, $771,491 and $3,247,037, respectively, at March 31, 2012. These factors raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. However, the operations of Phyhealth Sleep Care started generating revenue in the year ended December 31, 2011.

These conditions, as well as the conditions noted below, were considered when evaluating the Company’s liquidity and its ability to meet its ongoing obligations. These unaudited consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties.

Management plans to fund the needed cash flow by obtaining additional financing for the company. While management believes that this plan will provide the cash flow necessary to continue as a going concern, no assurances can be made that its plan will be successful.

Use of Estimates in Financial Statements - The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates during the period covered by these unaudited consolidated financial statements include the useful life of furniture, equipment and leasehold improvements, the allowance for contractual discounts and doubtful accounts, the impairment of long lived assets, valuation of securities, the valuation of stock issued for services, and the valuation allowance on deferred tax assets.

Phyhealth Corporation and Subsidiaries

Notes to Consolidated Financial Statements - Unaudited

For the three months ended March 31, 2012 and 2011

Revenues, Patient Accounts Receivable and Allowances – For the Company’s Sleep Care operations, the Company records revenue when persuasive evidence of an arrangement exists, services have been rendered, the sales price to the patient is fixed or determinable, and collectability is reasonably assured. The Company recognizes revenues in the period in which services are performed and billed to the patient or third party insurer. Patient accounts receivable primarily consist of amounts due from third party insurers and patients. Amounts the Company receives for treatment of patients is generally covered by third party insurers such as health maintenance organizations, preferred provider organizations and other private insurers and are generally less than the Company’s established billing rates. Accordingly, the revenues and related patient accounts receivable reported in the Company’s unaudited consolidated financial statements are recorded at the net amount expected to be received.

The Company derives a significant portion of its revenues from third party insurers that receive discounts from our standard charges. The Company must estimate the total amount of these discounts to prepare its consolidated financial statements. The various managed care contracts under which these discounts must be calculated are complex and are subject to interpretation and adjustment. The Company estimates the allowance for contractual discounts on a payer-specific basis given its interpretation of the applicable regulations or contract terms. These interpretations sometimes result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management. Changes in estimates related to the allowance for contractual discounts affect revenues reported in the Company’s consolidated statements of operations in the period of the change.

Management may record estimates for doubtful accounts, which may be sustained in the collection of these receivables. Although estimates with respect to realization of the receivables are based on management’s knowledge of current events, the Company’s collection history, and actions it may undertake in the future, actual collections may ultimately differ substantially from these estimates. Receivables are written off when all legal actions have been exhausted.

At March 31, 2012 and December 31, 2011, patient accounts receivable were presented net of an allowance for contractual discounts of $56,016 and $67,749, respectively, and an allowance for bad debts of $4,668 and $5,646, respectively.

Impairment of Long-Lived Assets - The Company evaluates its long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the asset to the future net undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is the excess of the carrying amount over the fair value of the asset.

Intangible - accreditation - The Company tests intangible assets for impairment in accordance with the provisions of Financial Accounting Standards Codification (ASC) section 350, “Goodwill and Other Intangible Assets.” Accordingly, intangible assets are tested for impairment at least annually or whenever events or circumstances indicate that intangible assets might be impaired. As of March 31, 2012, no impairment on intangible assets was considered necessary.

The accreditation that gives rise to this asset is a Provisional Accreditation acquired on January 1, 2012 (See Note 4) which is amortized over the 10 month expected life. Accreditation from the American Academy Of Sleep Medicine is required in order for the sleep center to treat Medicare beneficiaries and certain commercially insured patients, including those patients insured by Anthem Blue Cross/Blue Shield of Colorado. The intangible accreditation asset reflected on the unaudited consolidated balance sheet is net of $6,645 amortization expense for the three months ended March 31, 2012.

Recent Accounting Pronouncements - The following is a summary of recent authoritative pronouncements that affect accounting, reporting, and disclosure of financial information by the Company.

In May 2011, the FASB issued ASU No. 2011-04, “Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and International Financial Reporting Standards (“IFRS”).” The amendments in this ASU generally represent clarification of Topic 820, but also include instances where a particular principle or requirement for measuring fair value or disclosing information about fair value measurements has changed. This update results in common principles and requirements for measuring fair value and for disclosing information about fair value measurements in accordance with GAAP and IFRS. The amendments are effective for interim and annual periods beginning after December 15, 2011 and are to be applied prospectively. Early application is not permitted. The Company does not expect that the adoption of ASU 2011-04 will have a material impact on its consolidated financial statements.

Phyhealth Corporation and Subsidiaries

Notes to Consolidated Financial Statements - Unaudited

For the three months ended March 31, 2012 and 2011

In June 2011, the FASB issued ASU 2011-05, “Comprehensive Income (Topic 220): Presentation of Comprehensive Income.” Specifically, the new guidance allows an entity to present components of net income or other comprehensive income in one continuous statement, referred to as the statement of comprehensive income, or in two separate, but consecutive statements. The new guidance eliminates the current option to report other comprehensive income and its components in the statement of changes in equity. While the new guidance changes the presentation of comprehensive income, there are no changes to the components that are recognized in net income or other comprehensive income under current accounting guidance. The new guidance is effective for fiscal years and interim periods beginning after December 15, 2011 and is to be applied retrospectively. The Company does not expect that the adoption of ASU 2011-05 will have a material impact on its consolidated financial statements.

2. INVESTMENTS IN SECURITIES

Investments made by the Company in equity securities as of March 31, 2012 are as follows:

Marketable Equity Securities:

ZST Digital Networks, Inc. Common Stock – In November 10, 2010 Spinoff, the Company received 75,000 shares of common stock in ZST Digital Networks, Inc. (ZST Digital), a Chinese supplier of optical and digital network equipment, listed as ZSTN on NASDAQ.

During the three months ended March 31, 2012 and 2011, the Company sold shares of ZST Digital common stock with a market value of $0 and $427,486, respectively. In the three months ended March 31, 2011 the Company received proceeds after selling costs of $423,543 realizing a gain of $147,855. In addition, an unrealized loss of $0 and $59,357 is reflected in the unaudited consolidated statements of operations and comprehensive loss for the three months ended March 31, 2012 and 2011, respectively. All shares of this stock were sold in 2011 and all gains and losses have been realized.

Bio-Matrix Scientific Group, Inc. (Bio-Matrix) Common Stock – In the November 10, 2010 Spinoff, the Company received 1,150,000 common shares and 25,000 of non-convertible preferred shares of Bio-Matrix Scientific Group (Bio-Matrix). Bio-Matrix is an OTCBB company listed as BMSN. This investment in common stock is classified as available for sale by management and presented as short-term because the shares are expected to be sold in the next twelve months. The preferred shares are non-marketable and valued at zero cost (see below). There is a possibility that the Company could receive an additional 150,000 shares of Bio-Matrix common stock that Bio-Matrix issued to another entity under the original PHMG purchase agreement as compensation for a business transaction that never materialized. Since that transaction never materialized, the Company believes that they should receive the shares of Bio-Matrix common stock issued to that entity. However, those shares have not been recognized in these consolidated financial statements nor included in the fair value disclosure herein, because it is not reasonably assured that they will receive those shares.

Based on the OTC market price of the stock currently held by the Company, an unrealized gain of $6,785 and an unrealized loss of $10,350 is reflected in the unaudited consolidated statements of operations and comprehensive loss for the three months ended March 31, 2012 and 2011, respectively. The fair value of these securities as of March 31, 2012 reflected in the accompanying unaudited consolidated balance sheet is $9,200.

Phyhealth Corporation and Subsidiaries

Notes to Consolidated Financial Statements - Unaudited

For the three months ended March 31, 2012 and 2011

Non-Marketable Securities:

Bio-Matrix Scientific Group, Inc. (Bio-Matrix) Preferred Stock – As described above the Company acquired 25,000 shares of non-convertible preferred stock in Bio-Matrix. These shares were recorded at a zero cost basis.

Common stock - MLH Investments, Inc. (MLH) – On November 10, 2010 the Company acquired PHMG’s interest in 100,000 restricted common shares of Wound Management Technologies, Inc. (WNDM) common stock that was provided to PHMG as a result of a previous loan made to MLH. The Company also received a put option requiring MLH to purchase 75,000 shares of the WNDM stock at $3.00 per share upon notice by the Company between September 15, 2009 and October 15, 2009. Although the original loan was repaid, MLH and WNDM have refused to honor the terms of these other instruments and have not issued the 100,000 shares of WNDM common stock to the Company and have not paid the $225,000 due upon the Company’s exercise of the Put Option. The Company believes the terms are legally enforceable and has filed a lawsuit against MLH Investments, its Chairman, WNDM and other parties. However, the Company has not recorded the stock in these financial statements since a positive outcome to this dispute cannot be reasonably assured.

Note Receivable and warrants from Bottled Water Media (BWM) - On November 10, 2010 the Company acquired PHMG’s interest in a note receivable of $250,000 in BWM in the form of a secured original issue discount promissory note with a face value of $287,500, including interest, with a maturity date of December 29, 2009, collateralized by the intellectual property of BWM and the Chief Executive Officer’s personal guarantee. Part of the compensation to the Company includes warrants to purchase 7% of the BWM’s common stock and 7% of the BWM’s preferred stock for $200,000, which expires on December 29, 2012. Since BWM is a privately held development stage company with no revenues or sales contracts and no indicators of common stock value, the warrant received was valued at zero for accounting purposes and no interest or loan fee income was recognized. Since the warrants are accounted for at cost for this non-marketable security, there is no change in recorded value as of December 31, 2011. BWM has the right to repurchase 50% of the Warrants from the Company for $500,000. The Company is also entitled to future advertising through BWM at BWM’s cost for a period of 24 months not to exceed $250,000 or 25% of BWM’s annual revenues.

Since BWM is in default on this note receivable, default interest rates of 27% started to accrue, the warrant to purchase 7% of BWM’s common stock and preferred stock increased to 20% and the exercise price was reduced to $100. While the Company’s management remains hopeful that they will be repaid their investment and earnings from this note receivable, due to the uncertainty of BWM’s ability to raise funds and BWM’s lack of established operations, the Company has maintained a 100% reserve that was established prior to November 10, 2010 acquisition of this investment in BWM and no interest income is being accrued.

3. FAIR VALUE MEASUREMENTS

Marketable Equity Securities

As of March 31, 2012 the Company’s investments in marketable equity securities are based on the March 31, 2012 stock price as reflected in the OTC markets. These marketable equity securities are summarized as follows:

	Equity Securities Cost		Aggregate Unrealized Gains (Loss)			Equity Securities Aggregated Fair Value
Marketable Equity Securities-Available for Sale:

Bio-Matrix Scientific Group, Inc.		105,000		(95,800	)		9,200

Total Marketable Equity Securities-Available for Sale	$	105,000	$	(95,800	)	$	9,200

Phyhealth Corporation and Subsidiaries

Notes to Consolidated Financial Statements - Unaudited

For the three months ended March 31, 2012 and 2011

The unrealized income (losses) are presented in the comprehensive loss portion of the consolidated statements of operations and comprehensive loss and is included in the accumulated other comprehensive income – unrealized income (loss) on marketable equity securities on the balance sheet.

The levels of the fair value measurements for marketable equity securities are summarized as follows:

	Fair Value Measurements Using:
	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Marketable Equity Securities – December 31, 2011	$	2,415	$	-	$	-

Sale of equity securities		-		-		-

Total unrealized gains (losses)
included in other comprehensive income		6,785		-		-

Marketable Equity Securities – March 31, 2012	$	9,200	$	-	$	-

4. SLEEP CENTER ACQUISITION

On January 1, 2012 (“closing date”), the Company acquired all the business and assets of Z-sleep Diagnoztics, Inc., a Colorado corporation for 150,000 shares of the Company common stock, issued February 14, 2012, and valued at $0.083 per share based on the quoted trading price on the closing date, or $12,450, plus two payments of $7,500 due on April 1, 2012 and July 1, 2012, for a total purchase price of $27,750. The allocation of the final purchase price is summarized as follows:

Fair market value of assets acquired:
Provisional accreditation - American Academy of Sleep Medicine	$	22,150
Furniture, equipment and supplies		5,300
Total fair value of assets purchased	$	27,450

The assets were recorded at their fair market value and the purchase price was recorded as a liability until the common shares were issued on February 14, 2012 and the payments are made.

The Company also entered into a three year operating lease for the operating facilities of this sleep center. The minimum lease payments under this lease are as follows:

Years ended March 31,	Amount
2013	$	23,700
2014		24,400
2015		8,200
Total	$	56,300

The operating expenses subsequent to the January 1, 2012 acquisition have been included in the consolidated statement of operations and comprehensive loss as of March 31, 2012. The Company received its first revenues in January 2012 from these operations. The Company purchased these assets primarily for the provisional accreditation held by Z-sleep Diagnoztics, Inc.

Pro forma financial disclosures have not been presented since the financial impact of the Sleep Center operation was not material to the Company’s consolidated financial statements.

Phyhealth Corporation and Subsidiaries

Notes to Consolidated Financial Statements - Unaudited

For the three months ended March 31, 2012 and 2011

5. LITIGATION

The Company is not a defendant in any litigation.

An investor in the Company’s former parent corporation, Physicians Healthcare Management Group Inc. (PHMG), has initiated litigation against PHMG. The investor asserts that the August 2008 exchange of PHMG's convertible debenture, issued by PHMG to such investor, for PHMG Series B Preferred shares, should be voided. The investor claims that its own former Investment Advisor had conflicting interests, alleging that its Investment Advisor also represented PHMG at that time.

The investor seeks to have the conversion, executed by PHMG and the investor’s former Investment Advisor, declared void, so that the convertible debenture, with PHMG, in an amount of $263,000, plus accrued interest, would remain a convertible debenture with PHMG instead of preferred stock with PHMG. PHMG believes this case is without merit and has asked its legal counsel to vigorously contest this matter. The investor’s former Investment Advisor and PHMG deny that there was any conflict of interest and deny any wrongdoing in this exchange, and deny any other circumstance which would enable the investor to retroactively avoid the exchange. After discovery in the litigation is complete, PHMG's legal counsel plans to file a motion for summary judgment, as its legal counsel sees no factual basis for the complaint. PHMG’s management believes it will successfully defend this claim and does not believe that the outcome of this litigation will have a material impact to PHMG’s consolidated financial statements. The Company's management does not believe that the outcome of this litigation will have any impact on the Company's consolidated financial statements. Accordingly, no liability has been recorded in PHMG's financial statements or the Company’s unaudited consolidated financial statements regarding this litigation between PHMG and the PHMG investor.

6. RELATED PARTIES

The Company has contracted with NextPath Partners, LLC (NextPath) to provide full-time marketing and related services for $7,500 per month to support the introduction and sales of Physhield’s medical malpractice products, particularly in Maryland and the District of Columbia. Services include website development and maintenance, product development, communications, and direct marketing to physicians. NextPath has also been engaged by the Company to provide substantially the same full-time marketing services to Phyhealth Sleep Care Corporation. NextPath will not receive additional compensation for the services for Sleep Care over and above the $7,500 per month contracted amount. NextPath is owned and operated by the spouse of the President and CEO of the Company. NextPath has more than twenty years executive management experience in target marketing for a Fortune 500 media corporation and complies with the Company’s Related Parties Policy. Next Path was paid $0 and $7,500 for the three months ended March 31, 2012 and 2011, respectively. The Company owes Next Path $37,500 as of March 31, 2012 for services provided from November 2011 to March 2012.

Extinguishment/Repayment of Note Payable to Related Party – On February 17, 2012, the Company agreed to offset 1) a $21,656 related party receivable resulting from 2011 costs paid on behalf of Physicians Healthcare Management Group, Inc. (an affiliate) and 2) any and all rights to certain investments that it had previously written-off, against the note payable of $50,000 owed to Physicians Healthcare Management Group, Inc. Since the Company recognized a 100% impairment loss on the investment in 2011, it recognized a gain of $28,344 on February 17, 2012 when offsetting the $50,000 note payable against the assets described above.

Loan payable to related party officer and spouse – In the three months ended December 31, 2011 and the three months ended March 31, 2012 the President/Chief Executive Officer/Chairman of the Board and his spouse made unsecured, 12% interest loan to the Company of $25,000 and $170,000, respectively. These loans are due on demand and were used for general operating expenses. Interest totaling $3,021 has accrued on these loans along with $20,257 of accrued interest on convertible note payable that was also loaned by this officer and his spouse. The total $218,278 of interest and the unsecured loan is presented on the consolidated balance sheet as loan payable to related party officer and his spouse.

Phyhealth Corporation and Subsidiaries

Notes to Consolidated Financial Statements - Unaudited

For the three months ended March 31, 2012 and 2011

7. CONVERTIBLE NOTES PAYABLE – RELATED PARTY

The President/Chief Executive Officer/Chairman of the Board (CEO) and his Spouse has loaned the Company $300,000 in exchange for convertible notes payable, as summarized as follows:

Investor	Date of loan	Common Shares Issue		Loan Amount
President/CEO/Chairman of the Board	8/9/2011		250,000	$	100,000
President/CEO/Chairman of the Board	8/26/2011		250,000		100,000
Spouse of President/CEO/Chairman of the Board	10/6/2011		500,000		100,000
			1,000,000	$	300,000

On August 9, 2011, the Company executed a convertible note payable with its President/Chief Executive Officer/Chairman of the Board (CEO), whereby the Company would draw down loans from the CEO up to four times at increments of at least $25,000, for a total maximum of $100,000. The CEO advanced all $100,000 on this note in August 2011 under three draws. The note earns 12% interest per annum, payable on the maturity date of November 9, 2011, plus 250,000 shares of the Company’s common stock payable and issued on August 9, 2011. The CEO has the option to convert the note and accrued interest at $0.28 per share, unless the note is in default, at which time the conversion rate changes to $.14 per share. The Company has defaulted on this note.

The 250,000 shares of common stock issued with the debt, which represents a loan fee, was recorded at their relative fair value of $19,444 with a corresponding debt discount. Additionally, a beneficial conversion value of $5,556 was recorded as a debt discount and additional paid-in capital. Both discounts are being amortized to interest expense over the term of the note. The subsequent draws, totaling $75,000, caused additional beneficial conversion values of $18,750 to be recorded and to be amortized over the remaining term of the loan. There is also a contingent beneficial conversion value due to the default of the Company that totals $56,250. This contingent beneficial conversion value was recorded as of the date of the default. The default caused a decrease in the conversion price of the note to $.14 per share.

On August 26, 2011, the Company executed a second 12% convertible note payable with its President/Chief Executive Officer/Chairman of the Board (CEO), with the exact same terms as described above, maturing November 26, 2011. The 250,000 shares of common stock issued with the debt, which represents a loan fee, was recorded at their relative fair value of $19,444 with a corresponding debt discount. Additionally, a beneficial conversion value of $5,556 was recorded as a debt discount and additional paid-in capital. Both discounts are being amortized to interest expense over the term of the note. The subsequent draws, totaling $75,000, caused additional beneficial conversion values of $18,750 to be recorded and amortized over the remaining term of the loan. There is also a contingent beneficial conversion value due to the default of the Company that totals $56,250. The default caused a decrease in the conversion price of the note to $.14 per share.

On October 6, 2011, the Company executed a convertible note payable with the spouse of its President/Chief Executive Officer/Chairman of the Board (CEO), whereby the Company would draw down loans up to four times at increments of at least $25,000, for a total maximum of $100,000. The CEO’s spouse advanced all $100,000 on this note in October 2011 under two draws. The note earns 12% interest per annum, payable on the maturity date of January 6, 2012, plus 500,000 shares of the Company’s common stock payable as a loan fee and issued on October 6, 2011. The holder has the option to convert the note and accrued interest of $0.0664 per share, unless the note is in default, at which time the conversion rate will change to $0.0415 per share. The Company has subsequently defaulted on this note.

The 500,000 shares of common stock issued with the debt, which represents a loan fee, was recorded at their relative fair value of $27,322 with a corresponding debt discount. Additionally, a beneficial conversion value of $22,678 was recorded as a debt discount and additional paid-in capital. Both discounts are being amortized to interest expense over the term of the note. The subsequent draw of $50,000 caused additional beneficial conversion values of $8,300 to be recorded and to be amortized over the remaining term of the loan. There is also a contingent beneficial conversion value due to the default of the Company that totals $30,000. This contingent beneficial conversion value was recorded as of the date of the January 6, 2012 default on the note and expensed immediately. The default caused a decrease in the conversion price of the note to $0.0415 per share.

Phyhealth Corporation and Subsidiaries

Notes to Consolidated Financial Statements - Unaudited

For the three months ended March 31, 2012 and 2011

Interest expense of $33,876 was recorded as a result of the amortization of debt discount from the convertible notes payable for the three months ended March 31, 2012. The Company also recorded $8,975 of accrued interest on the convertible notes for the three months ended March 31, 2012, for total accrued interest expense owed on these notes of $19,833 at March 31, 2012.

8. STOCKHOLDERS’ EQUITY

On January 1, 2012, the Company issued 150,000 shares of its common stock in the acquisition in of a sleep center as described in Note 4. The shares were valued at $0.083 per share or $12,450 based on the quoted trading price on the closing date of issuance.

On January 6, 2012, the Company defaulted on the third convertible note payable to the spouse of its President/Chief Executive Officer/Chairman of the Board (CEO) as fully described in Note 7. As a result of that default the Company recorded an additional $30,000 beneficial conversion and expensed it immediately with a credit to additional paid in capital.

9. SUBSEQUENT EVENTS

Reverse Stock Split and Stock Sale - On April 2, 2012 the Company signed a “Stock Acquisition Agreement” (Agreement) whereby Queste Capital (Queste) will purchase approximately 95% of the Company’s common stock for $425,000. Prior to the purchase the Agreement calls for the Company to declare a 1 for 12 reverse stock split for all classes of stock and then subsequently issue additional shares to Queste Capital and its investors. After the transaction the Company will have approximately 84,500,000 common shares outstanding and approximately 95% of those shares will be owned by Queste Capital and its investors. The reverse split and stock sale are not completed as of the date of this report.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our financial statements.

The purpose of this discussion is to provide an understanding of the financial results and condition of Phyhealth Corporation (Company) and to also describe the plans for future growth and expansion.

Forward-Looking Statements

This Management’s Discussion and Analysis and other parts of this report contain forward-looking statements that involve risks and uncertainties, as well as current expectations and assumptions. From time to time, the Company may publish forward-looking statements, including those that are contained in this report, relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research and development activities and similar matters. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. In order to comply with the terms of the safe harbor, the Company notes that a variety of factors could cause the Company’s actual results and experience to differ materially from the anticipated results or other expectations expressed in the Company’s forward-looking statements. The risks and uncertainties that may affect the operations, performance, development and results of the Company’s business include, but are not limited to, its ability to maintain sufficient working capital, adverse changes in the economy, the ability to attract and maintain key personnel, its ability to identify or complete an acceptable merger or acquisition, and future results related to acquisition, merger or investment activities. The Company’s actual results could differ materially from those anticipated in these forward-looking statements, including those set forth elsewhere in this report. The Company assumes no obligation to update any such forward-looking statements.

Operational Overview:

The Company was dormant during 2008, 2009 and most of 2010. The Company was created to receive the business, operating assets and liabilities of Physician Healthcare Management Group, Inc. (PHMG) under a spinoff where shares of the Company are distributed to the stockholders of PHMG and both PHMG and the Company became independent publicly traded companies. That spinoff occurred on November 10, 2010.

During 2011, the Company received its first revenues from services provided by its wholly owned subsidiary Phyhealth Sleep Care Corporation as more fully described below. The receipt of these revenues means that the Company is no longer a “development stage enterprise” for financial accounting purposes. Although several portions of the business plan are still to be implemented, it is now considered to be an operating entity.

The Company’s intended core product is the development of community health plans-based on a health maintenance organization (HMO) license-that is owned and operated in partnership with the participating physicians. The Company’s community health plans are structured to integrate all the financial and reimbursement components of healthcare delivery; align the financial incentives of all participants; and empower physicians to assume end-to-end management of healthcare for their patients. The Phyhealth community health plan model is built on the foundation of the physician-patient relationship and rewards physicians for proactively providing the preventative care necessary to keep their patients healthy and for closely managing the ongoing care necessary for patients who suffer from chronic disorders to stabilize their health status.

Through its community health plan operations, the Company intends to expand its product offerings to include ownership and operation of local healthcare facilities and other products and services designed to support its goal to increase physicians’ income, reduce their expenses and add to their net worth. Part of this plan was initiated in October 2010 when the Company incorporated a wholly owned subsidiary named Phyhealth Sleep Care Corporation (Sleep Care) and entered into an agreement with an individual operator to open a series of sleep care centers over the next year. In November 2010, Sleep Care initiated the development of a 2-bed diagnostic sleep center in Longmont, Colorado and purchased the assets and assumed certain liabilities of an existing 2-bed diagnostic sleep care center in Denver, Colorado. In January 2011, the Denver facility was expanded to 4 beds. In June 2011, Sleep Care opened a 4-bed diagnostic sleep center in Virginia. In December 2011, the Company closed the Denver facility coincident with the expiration of the leases for this facility, and in January 2012, the Company purchased a 2-bed facility in Brighton, Colorado.

Results of Operations for the three months ending March 31, 2012 compared to the three months ending March 31, 2011

Sleep care operations:

The sleep care services revenue recognized for the three months ended March 31, 2012 included three sleep centers: one four-bed facility and one two-bed facility, a total of six beds, that were fully operational and one two-bed facility that was only marginally operational during the three months ended March 31, 2012. This is compared to sleep care service revenue resulting from two facilities with a total of six beds for the three months ended March 31, 2011. Revenue increased from $53,243 to $107,253 for the three months ended March 31, 2011 to the same time period in 2012.

The sleep care operating expenses increased from $109,521 to $191,434 for the three months ended March 31, 2011 compared to the three months ended March 31, 2012, respectively. The medical professional fees included in these amounts increased from $82,908 to $155,864 during these same time periods, respectively. Also included in sleep care operating expenses was rent expense that increased from $17,878 to $31,249 during the three months ended March 31, 2011 to March 31, 2012, respectively.

Corporate expenses:

Officer and director compensation of $85,415 and $79,901 for the three months ended March 31, 2012 and 2011, respectively, was incurred in accordance with the employment contracts of the two executive officers of the Company. However, of the $85,415 compensation for the three months ended March 31, 2012, the Company still owes two executives $62,500 because there was not sufficient cash to pay their compensation under their contracts. As of March 31, 2012, the Company owes the two executives a total of $131,013 in unpaid compensation.

Consulting and professional fees totaled $47,311 and $100,206 for the three months ended March 31, 2012 and 2011 and consisted mostly of legal, audit and accounting fees incurred in the completion of the Company’s Form 10K and other day to day operating matters.

Bad debt expense of $29,917 for the three months ended March 31, 2011 was a result of recording the allowance for doubtful accounts for all costs due to the Company by Physhield Insurance Exchange, a Risk Retention Group. Since the Physhield Risk Retention Group was terminated, the Company will not be reimbursed for these costs.

The Company’s general and administrative expenses totaling $106,344 and $80,591 for the three months ended March 31, 2012 and 2011, respectively. The increase is due to an increase in depreciation on leased equipment and amortization of intangible assets.

Liquidity and Capital Resources

The Company’s cash and liquidity resources have been provided by the assets received in the November 10, 2010 spin-off. As of the date of the spin-off, the Company received $118,127 in cash and $1,061,000 of marketable equity securities and a surplus note receivable. During the year ended December 31, 2011, management sold a portion of the marketable equity securities for $436,462 and liquidated the surplus note receivable for $427,875. Additionally, the President, Chief Executive Officer and Chairman of the Board (CEO) and his spouse have loaned the company $300,000 in convertible notes payable and $25,000 in short-term loans in the year-ended December 31, 2011. These funds have been used to fund the startup of Phyhealth Sleep Centers and to meet general corporate expenses.

Subsequent to 2011, the President, Chief Executive Officer and Chairman of the Board (CEO) and his spouse have loaned the Company an additional $170,000 in short-term unsecured loans with 12% interest to fund the operations of the Company. These loans are due on demand.

The Company is currently out of funds and is looking for additional financing in order to support the sleep care business as well as administrative expenses. On April 2, 2012, in order to raise funds the Company has entered into a transaction that would sell its common stock that is approximately 95% of its fully diluted ownership interest for $425,000. (See subsequent events, Note 8) However, there is no guarantee that this, or any other, funding can be finalized.

Off-Balance Sheet Arrangements

None

Debt and Contractual Obligations

As a result of the spin-off on November 10, 2010, the Company assumed the two employment agreements, one with its President/Chief Executive Officer/Chairman of the Board (CEO), the other with its Vice President, Chief Operating Officer and Corporate Director (COO). Both agreements are effective upon signing and expire on December 31, 2012. The base salary of the two agreements total $270,000, with combined escalation clauses up to $900,000 if certain revenue, equity and profit milestones are met.

The Company has lease commitments for corporate office space and three sleep care operational facilities. The minimum operating lease payments under all four facility leases total:

Year ended March 31:	Amount
2013	$	139,900
2014		144,200
2015		29,200
Total	$	313,300

The Company is also obligated to monthly payments under three year equipment capital leases are as follows:

Year ended March 31:	Amount
2013	$	88,200
2014		69,100
2015		14,000
Total	$	171,300

Critical Accounting Policies

Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States. On an ongoing basis we re-evaluate our judgments and estimates including those related to bad debts, investments and income taxes. We base our estimates and judgments on our historical experience, knowledge of current conditions and our beliefs of what could occur in the future considering available information. Actual results may differ from these estimates under different assumptions or conditions. Our estimates are guided by observing the following critical accounting policies.

Patient Revenues:

The Company recognizes revenues in the period in which services are performed and billed to the patient or third party insurer. Amounts the Company receives for treatment of patients is generally covered by third party insurers and is generally less than the Company’s established billing rates. Accordingly, the revenues and related accounts receivable reported in the Company’s unaudited consolidated financial statements are recorded at the net amount expected to be received.

The Company derives a significant portion of its revenues from third party insurers that receive discounts from our standard charges. The Company must estimate the total amount of these discounts to prepare its consolidated financial statements. The various managed care contracts under which these discounts must be calculated are complex and are subject to interpretation and adjustment. The Company estimates the allowance for contractual discounts on a payor-specific basis given its interpretation of the applicable regulations or contract terms. These interpretations sometimes result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management. Changes in estimates related to the allowance for contractual discounts affect revenues reported in the Company’s unaudited consolidated statements of operations in the period of the change.

Allowance for loans:

Phyhealth's predecessor loaned funds to several companies and have subsequently recorded a 100% allowance on those investments because the uncertainty regarding the investee’s ability to repay the loan. However, if those investees are able to repay the loan it would create material expense recovery to the Company’s financial statements. In one such investment, Phyhealth, as the successor, is entitled to 20% of the company for $100 and could gain much more than the original investment by having a 20% ownership interest in the company along with the intellectual property it possesses.

Income taxes

Phyhealth accounts for income taxes using the liability method, which requires the determination of deferred tax assets and liabilities based on the differences between the financial and tax basis of assets and liabilities, using enacted tax rates in effect for the year in which differences are expected to reverse. Deferred tax assets are adjusted by a valuation allowance, if based on the weight of available evidence it is more likely than not that some portion or all of the deferred tax assets will not be realized. Currently 100% of the deferred tax asset is reserved. If in fact Phyhealth does become profitable post spin-off, income will be charged to the statement of operations resulting from a reversal of that allowance. That allowance totals approximately $2.8 million as of December 31, 2011.

Recent Accounting Pronouncements

The following is a summary of recent authoritative pronouncements that affect accounting, reporting, and disclosure of financial information by the Company.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures- Our management carried out an evaluation, with the participation of our Principal Executive Officer and Principal Financial Officer, required by Rule 13a-15 of the Securities Exchange Act of 1934 (Exchange Act) of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Exchange Act. Based on their evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified under SEC rules and forms and is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting. There were no changes in our internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

There have not been any material civil, administrative or criminal proceedings concluded, pending or on appeal against Phyhealth, or its respective affiliates and principals. However, PHMG is a party to two separate legal proceedings, both of which were pending during the reporting period. Since Phyhealth is the successor to PHMG, for most purposes, it has assumed the pursuit of the matter in which PHMG is the plaintiff and it may inherit the obligations associated with the action in which PHMG is the defendant. We know of no legal proceedings pending or threatened or judgments against the Company or against any director or officer of the Company in his or her capacity as such.

An investor in the Company’s former parent corporation, Physicians Health Management Group Inc. (PHMG), has initiated litigation against PHMG. The investor asserts that the August 2008 exchange of PHMG's convertible debenture, issued by PHMG to such investor, for PHMG Series B Preferred shares, should be voided. The investor claims that its own former Investment Advisor had conflicting interests, alleging that its Investment Advisor also represented PHMG at that time.

The investor seeks to have the conversion, executed by PHMG and the investor’s former Investment Advisor, declared void, so that the convertible debenture, with PHMG, in an amount of $263,000, plus accrued interest, would remain a convertible debenture with PHMG instead of preferred stock with PHMG. PHMG believes this case is without merit and has asked its legal counsel to vigorously contest this matter. The investor’s former Investment Advisor and PHMG deny that there was any conflict of interest and deny any wrongdoing in this exchange, and deny any other circumstance which would enable the investor to retroactively avoid the exchange. After discovery in the litigation is complete, PHMG's legal counsel plans to file a motion for summary judgment, as its legal counsel sees no factual basis for the complaint. PHMG’s management believes it will successfully defend this claim and does not believe that the outcome of this litigation will have a material impact to PHMG’s consolidated financial statements. The Company's management does not believe that the outcome of this litigation will have any impact on the Company's consolidated financial statements. Accordingly, no liability has been recorded in PHMG's financial statements or the Company’s consolidated financial records regarding this litigation between PHMG and the PHMG investor.

On May 15, 2009, PHMG invested $250,000 with a Mr. Scott Haire and MLH, Inc. (MLH), a provider of specialty medical, biotechnology solutions and technology applications. The investment was for Wound Management Technologies, Inc. (OTCBB: WNDM) common stock and a 10% Secured Promissory Note (the “Note”) which was originally due June 15, 2009. This is among the assets assumed by Phyhealth, post-spinoff. Following several amendments and extensions, the monetary portion of the Note was paid in full in August 2009. However, part of the consideration received for making the investment and extending repayment, was 100,000 restricted common shares of Wound Management common stock. In addition, the Note, as amended included a Put Option requiring MLH and Scott Haire to purchase 75,000 shares of the WNDM stock at $3.00 per share. However, Scott Haire, MLH and Wound Management have refused to honor the terms of the Note, as amended, and have not issued the 100,000 shares of WNDM common stock to PHMG and have not paid the $225,000 due upon PHMG’s exercise of the Put Option. Management believes the terms of the Note as amended are legally enforceable and has accordingly filed suit against Wound Management, Scott Haire and MLH and other parties. The suit sounds in breach of contract and fraud. While Management is confident of its position in this suit, there is no assurance that there will be a positive outcome to this dispute or that the defendants will be capable of satisfying any judgment.

ITEM 1A. RISK FACTORS

Not applicable since Phyhealth is a "small reporting company" as defined and therefore exempt from providing in this Report.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

None

SIGNATURES (*)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PHYHEALTH CORPORATION

Date May 21, 2012	By:	/s/ Robert L Trinka
		Robert L. Trinka,
		Chairman, President, CEO,
		Principal Executive Officer and Principal Financial


Date May 21, 2012	By:	/s/ Fidel Rodiguez
		Fidel Rodriguez,
		V.P./Chief Operating Officer, Director and Treasurer

Attached files

Stock widget

Investing forum

PHYHEALTH Corp Reports

Also read